Kelyniam Global Inc. Announces Record Revenues

Third Quarter

Kelyniam is pleased to announce record quarterly revenues of $382,177 for the third quarter ending September 30th 2012. This represents almost double the product revenue produced in the second quarter 2012. The company continues to penetrate the custom cranial implant marketplace and has sold implants to medical institutions in more than 20 different states. Furthermore, the company has sold the first maxiofacial implants in the fourth quarter as a result of the recent FDA 510k approval in late third quarter.

Fourth Quarter

The debut of Kelyniam maxiofacial implants in the fourth quarter was met with orders. These orders combined with existing custom cranial implant orders propelled revenues to approximately $400,000 for the fourth quarter, exceeding internal expectations of a slow quarter due to multiple holidays and fewer surgeries. Final fourth quarter numbers will be released once a full accounting is complete.

"The final two quarters of the year demonstrate that both the custom cranial and maxiofacial implant markets have capacity for a product of superior design. Management has worked hard to right the ship in 2012 and looks to build on the momentum in 2013" stated President and CEO Tennyson Anthony. "Kelyniam not only has created a product that fills the patient's cranial void, but is filling the void in the marketplace for a timely-delivered well-fitting product."

Upcoming Conference

Kelyniam will be exhibiting once again at the North American Skull Base Society (NASBS) February 15th - 17th, in Miami, FL.

Financial tables can be found on the company's website www.kelyniam.com

About Kelyniam Global, Incorporated

Kelyniam Global (Pinksheets: KLYG), Inc. specializes in the use of CAD/CAM technology to provide patient specific custom implants to assist medical professionals by allowing them to operate more effectively, improve patient care, and reduce health care costs by providing the highest quality products available with today's technology. The company is continually researching and developing new products and processes to help patients live more active and productive lives.

Please visit our website at www.kelyniam.com for more information.

Forward-Looking Statements

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as "anticipate," "believes," "estimate," "expect," "should," "intend," "projects," "objective" and "appears" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the impact of competitive products and pricing; capacity and supply constraints or difficulties; product development, commercialization or technological difficulties; the regulatory and trade environment; the impact of reimbursement rates and coverage; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to revise any forward-looking statements as a result of future events or developments.

Kelyniam Global (PK) (USOTC:KLYG)
Historical Stock Chart
From Nov 2024 to Dec 2024